About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Rapid Medical Donation Programme for Breast Cancer | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNNCT02126800

Rapid Medical Donation Programme for Breast Cancer

Treatment of breast cancer has traditionally been based on the primary tumour's features in the breast. Only recently, when cancer returns at other sites, has there been an attempt to biopsy the metas...

Lead sponsor: Royal Marsden NHS Foundation Trust•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Sally Bennett, RN

CONTACT

+44 (0)2073528171 LEGACY-BC@icr.ac.uk

Sponsors

Lead Sponsor

Royal Marsden NHS Foundation Trust

Collaborators

Breakthrough Breast Cancer
Institute of Cancer Research, United Kingdom

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients who have completed active treatment (or trials) for metastatic breast cancer.
•Patients referred to either community or the hospital-based palliative care unit from Royal Marsden National Health Service Foundation Trust.

Exclusion Criteria

•Lack of capacity / inability to give informed consent.
•Diagnosis of alternative cancer within the last 5 years other than resected basal cell skin cancer or cervical intraepithelial neoplasia.
•Patients known to be HIV, Hepatitis B virus or Hepatitis C virus positive on serology .
•Spongiform encephalopathy (known or suspected CJD) .
•Eligibility for or current participation in a clinical trial (excluding palliative care trials)

Related studies

Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy

NCT06994377 · Metastatic Breast Cancer

RECRUITINGPhase 2

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

NCT07222215 · Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, and more

RECRUITINGPhase 2

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

NCT02422641 · Metastatic Breast Cancer, Leptomeningeal Disease

RECRUITINGPhase 1/2

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

NCT06110793 · Metastatic Breast Cancer

RECRUITINGPhase 2

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

NCT06525766 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 30, 2014Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment60

Start dateMar 2014

Last updatedApr 30, 2014

Condition

Metastatic Breast Cancer

Locations shown

Royal Marsden NHS Foundation Trust

London

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 30, 2014Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions